Proceedings of the 2nd International Conference on Contemporary Science and Clinical Pharmacy 2021 (ICCSCP 2021)

<Previous Article In Volume
Next Article In Volume>

Adverse Events Following Immunization Report and Vaccine Effectiveness of Sinovac. An Interim Report

Authors
Abraham Simatupang1, *, Robert H Sirait2, Forman Erwin Siagian3, Yunita RMB Sitompul4, Luana Natingkaseh5, Sudung Nainggolan4
1Department of Pharmacology and Therapy, Faculty of Medicine – Universitas Kristen Indonesia, Jakarta
2Department of Anesthesiology, Faculty of Medicine – Universitas Kristen Indonesia, Jakarta
3Department of Parasitology, Faculty of Medicine – Universitas Kristen Indonesia, Jakarta
4Department of Public Health, Faculty of Medicine – Universitas Kristen Indonesia, Jakarta
5Department of Psychiatry, Faculty of Medicine – Universitas Kristen Indonesia, Jakarta
*Corresponding author: Email: abraham.simatupang@uki.ac.id
Corresponding Author
Abraham Simatupang
Available Online 17 November 2021.
DOI
10.2991/ahsr.k.211105.036How to use a DOI?
Keywords
AEFI; Sinovac; Covid-19
Abstract

Vaccination is a prevention of transmission and spread and in order to establish herd immunity against the Covid-19 pandemic. Indonesia chose the Sinovac vaccine, which uses weakened viruses. The objective of the study was to measure the Adverse Events Following Immunization (AEFI) 24-72 hours post-vaccination and its effect at three months after vaccination. An online survey was distributed to 1574 subjects who received the first dose, and 530 respondents (response rate 33.6%) who answered the questionnaire were sent the form again for the second dose, and 249 subjects responded (response rate 46.9%). From the first dose: 322 female (60.9%), 207 male (39.1%). There were 22 respondents who had fever on the first day and only five respondents on the second day. In addition, 147 (27.8%) felt pain in the injection site, nausea 30 respondents (5.7%), vomiting six persons, bloating 35 respondents (6.6%), and diarrhea ten respondents (1.9%). Fifty-nine respondents who got mild adverse events did nothing to ease their adverse events, 18 respondents took self-medication, 15 respondents consulted the doctors in the vaccination site. Only one respondent went to the nearby hospital for further therapy. Results from the second dose: As many 249 respondents (131 female, 108 male) answered respondents. The AEFI’s pattern was quite the same as the first dose.

Copyright
© 2021 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Download article (PDF)

<Previous Article In Volume
Next Article In Volume>
Volume Title
Proceedings of the 2nd International Conference on Contemporary Science and Clinical Pharmacy 2021 (ICCSCP 2021)
Series
Advances in Health Sciences Research
Publication Date
17 November 2021
ISBN
978-94-6239-450-6
ISSN
2468-5739
DOI
10.2991/ahsr.k.211105.036How to use a DOI?
Copyright
© 2021 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Cite this article

risenwbib
TY  - CONF
AU  - Abraham Simatupang
AU  - Robert H Sirait
AU  - Forman Erwin Siagian
AU  - Yunita RMB Sitompul
AU  - Luana Natingkaseh
AU  - Sudung Nainggolan
PY  - 2021
DA  - 2021/11/17
TI  - Adverse Events Following Immunization Report and Vaccine Effectiveness of Sinovac. An Interim Report
BT  - Proceedings of the 2nd International Conference on Contemporary Science and Clinical Pharmacy 2021 (ICCSCP 2021)
PB  - Atlantis Press
SP  - 251
EP  - 256
SN  - 2468-5739
UR  - https://doi.org/10.2991/ahsr.k.211105.036
DO  - 10.2991/ahsr.k.211105.036
ID  - Simatupang2021
ER  -